Drug Trial News

RSS

First-of-its-kind study to test a personalized vaccine in cancer patient

Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic.

15 Oct 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today that updated efficacy and safety data from the fully enrolled cohort of epithelioid sarcoma (ES) patients in its ongoing Phase 2 trial of tazemetostat will be presented in a poster discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress to be held October 19-23 in Munich, Germany.

10 Oct 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

8 Oct 2018

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.

8 Oct 2018

Neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients yields high response rate

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early.

8 Oct 2018

Lyra Therapeutics announces presentation of Phase 1 clinical data for LYR-210 in CRS patients

Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.

8 Oct 2018

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor.

7 Oct 2018

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.

5 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

RCIGM and IDbyDNA launch clinical trial to improve diagnostics for pediatric CNS infections

The Rady Children's Institute for Genomic Medicine and IDbyDNA, a metagenomics technology company translating microbial genomics into actionable information for healthcare providers, have launched a clinical trial to improve diagnostics for pediatric central nervous system infections.

3 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis.

3 Oct 2018

Scientists perform successful trial of new antibiotic on cancer reoccurrence after surgery

SCIENTISTS fighting cancer have carried out the first successful trial of the effects of the antibiotic Doxycycline on cancer reoccurrence in patients after surgery.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Drug Trial News

First-of-its-kind study to test a personalized vaccine in cancer patient

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

Neoadjuvant clinical trial of immune checkpoint blockade for melanoma patients yields high response rate

Lyra Therapeutics announces presentation of Phase 1 clinical data for LYR-210 in CRS patients

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

RCIGM and IDbyDNA launch clinical trial to improve diagnostics for pediatric CNS infections

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Human clinical trial of investigational calcification inhibitor generates promising results

Scientists perform successful trial of new antibiotic on cancer reoccurrence after surgery

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Cancer drug trials focus on progression-free survival and overlook health-related quality of life

Study using DFMO shows positive results for children with high risk neuroblastoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Gangrene-causing bacteria show promise as cancer treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News